FDA looks to prepare reviewers for complex submissions
This article was originally published in The Gold Sheet
Executive Summary
The Office of Pharmaceutical Science in FDA's Center for Drug Evaluation and Research is looking to prepare its reviewers for increasingly challenging drug applications as the agency begins to see the submission of novel and complex dosage forms. The office is seeking to find organizations that could deliver a professional development program "to ensure reviewers are current in state-of-the-art pharmaceutical manufacturing and technology," the agency said in a June 2 sources sought notice
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.